Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial

Gonasagrie Nair, Kenneth Ngure(University of Nairobi), Felix Muhlanga(University of Zimbabwe), Pippa Macdonald(Desmond Tutu HIV Foundation), Cindy Jacobson(University of Pittsburgh), Bekezela Siziba(University of Zimbabwe), Sharon L. Hillier(Magee-Womens Research Institute), Sherri Johnson(Family Health International 360), Tara McClure(Family Health International 360), Sybil Hosek(University of Illinois Chicago), John Steytler, Linda‐Gail Bekker(Desmond Tutu HIV Foundation), Krishnaveni Reddy(Perinatal HIV Research Unit), James F. Rooney(Gilead Sciences (United States)), Craig W. Hendrix(Unknown), Peter L. Anderson(University of Colorado Denver), Jared M. Baeten(University of Washington), Eunice Tahuringana(University of Zimbabwe), Thesla Palanee‐Phillips(University of the Witwatersrand), Edward Livant(University of Pittsburgh), Ariane van der Straten(University of California, San Francisco), Carolyne A. Akello, Morgan Garcia(Family Health International 360), Urvi M. Parikh(University of Pittsburgh), Rita Nakalega(MUJHU Research Collaboration), Connie Celum(University of Washington), Elizabeth R. Brown(Fred Hutch Cancer Center), Lydia Soto-Torres, Daniel Szydlo(University of Washington), Gakiema Milan(Desmond Tutu HIV Foundation), Katherine Bunge(Fred Hutch Cancer Center), Clemensia Nakabiito(Makerere University), Lisa Levy(Fred Hutch Cancer Center)
The Lancet HIV
October 25, 2023
Cited by 62


Related Papers